GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.

@inproceedings{Tewari2018GOG3A,
  title={GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.},
  author={Krishnansu S Tewari and Ignace Vergote and A Oaknin and Edwin Rosero {\'A}lvarez and Dana Meredith Chase and Stephanie Gaillard and Stephanie Lheureux and Danny Rischin and Alessandro D. Santin and Mary Feng and Morgan Mathias and Matthew G. Fury and Israel Lowy and B. Monk},
  year={2018}
}
TPS5600Background: Patients with recurrent and metastatic cervical carcinoma experience modest survival benefit with first-line platinum-based chemotherapy with or without bevacizumab. Those with p... 

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.

Cemiplimab: First Global Approval

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED